KSD-101 / Hengsai Bio - LARVOL DELTA

Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study (ASH 2023) - "Our current study shows that KSD-101 has excellent safety and good preliminary efficacy against EBV-associated Hematologic Neoplasms with efficient induction of immune responses. The results indicate that KSD-101 is a promising therapeutic reagent for the treatment of EBV-associated Hematologic Neoplasms. Larger prospective studies and longer follow-up time is needed to be conducted."

Clinical • P1 data • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • Rare Diseases • T Cell Non-Hodgkin Lymphoma • CD4 • CD8

DENDRITIC CELL-BASED VACCINES (KSD-101) AGAINST EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASES: RESULTS FROM AN ONGOING PHASE I CLINICAL STUDY (EHA 2025) - P1 | "AS of now, KSD-101 has demonstrated good safety and efficacy and could activate immune system. Our study highlights its potential as a promising therapeutic agent for the treatment of EBV-LPDs. Larger prospective studies and a longer follow-up period is needed to be conducted."

Clinical • P1 data • Epstein-Barr Virus Infections • Hemophagocytic lymphohistiocytosis • Immunology • Oncology • Rare Diseases • CD8

Dendritic cell–based vaccines (KSD-101) against EBV-associated lymphoproliferative diseases: Results from an ongoing phase I clinical study. (ASCO 2025) - P1 | "AS of now, KSD-101 has demonstrated good safety and efficacy and could activate immune system. Our study highlights its potential as a promising therapeutic agent for the treatment of EBV-LPDs. Larger prospective studies and a longer follow-up period is needed to be conducted."

Clinical • P1 data • Epstein-Barr Virus Infections • Hemophagocytic lymphohistiocytosis • Immunology • Oncology • Rare Diseases • CD8

KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Kousai Bio Co., Ltd.

New P1 trial • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Kousai Bio Co., Ltd. | Active, not recruiting ➔ Withdrawn

Trial withdrawal • Hematological Malignancies • Lymphoma • Oncology

DENDRITIC CELL-BASED VACCINES (KSD-101) AGAINST EBV-ASSOCIATED HEMATOLOGIC NEOPLASMS: RESULTS FROM AN ONGOING PHASE I CLINICAL STUDY (EHA 2024) - P1 | "AS of now, KSD-101 has been demonstrated good safety and efficacy and could activate immune system. Ourstudy indicates that the KSD-101 is a promising therapeutic reagent for the treatment of EBV-associatedhematologic neoplasms. Larger prospective studies and longer follow-up time are needed to be conducted."

Clinical • P1 data • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • CD8

KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P1 trial • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Kousai Bio Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Kousai Bio Co., Ltd. | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Lymphoma • Oncology

KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=9 | Enrolling by invitation | Sponsor: Kousai Bio Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Hematological Malignancies • Lymphoma • Oncology

KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Kousai Bio Co., Ltd.

New P1 trial • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=9 | Enrolling by invitation | Sponsor: Tongji Hospital | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Hematological Disorders • Hematological Malignancies • Oncology

KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Shanghai Changhai Hospital

New P1 trial • Hematological Malignancies • Lymphoma • Oncology

KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Tongji Hospital

New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology